CEO Danny Yeung Buys $502K of Prenetics Stock in Open Market
PRE has more than doubled off its 52-week low of $7.175 on elevated volume (1.9× avg).
Summary
Prenetics CEO Danny Yeung bought $502K of company stock in the open market on August 20-24, 2026, at $18.31-$21.40 per share, following strong Q2 results and raised guidance.
Key Events · Ownership and Investor Activity · PRE
-
CEO Open-Market Purchase
Danny Sheng Wu Yeung bought 24,681 Class A Ordinary Shares for $501,998.40 across three transactions on August 20 and August 24, 2026, at prices from $18.31 to $21.40.
-
RSU Exercise
Exercised 53,953 RSUs (post 1-for-15 reverse split) on August 20, 2026, with no cash outlay.
-
Domestic Relations Transfer
Transferred 49,912 shares to ex-spouse pursuant to a domestic relations order on August 20, 2026 — a non-market disposition, not a sale.
-
Post-Transaction Holdings
Direct holdings stand at 137,647 shares following the transactions.
Analysis · PRE · Life Sciences
CEO Danny Sheng Wu Yeung purchased 24,681 Class A Ordinary Shares for $501,998.40 across three open-market transactions on August 20 and August 24, 2026, at prices between $18.31 and $21.40. This is real money out of pocket — not an option exercise or grant — and comes just days after the company reported Q2 revenue up 288% YoY and raised FY2026 guidance to $220-230M. The purchase represents roughly 0.13% of the company's market cap, a meaningful personal commitment from the chief executive. The filing also discloses a 49,912-share transfer to his ex-spouse under a domestic relations order, which is a non-market disposition and does not reflect a change in his investment view.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 29.5% of the 1457 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRE was trading at $21.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $374.1M. The 52-week trading range was $7.18 to $23.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.